NASDAQ · PACB
Healthcare · Medical - Devices
$1.34
Up+$0.00 (+0.00%)
Updated Sep 17, 2026, 1:54 AM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
PACB does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning PACB.
PACB research
Company profile and research snapshot.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 11, 2026 | Barclays | Underweight | — |
| Apr 14, 2026 | Barclays | Underweight | — |
| Mar 6, 2026 | Barclays | Underweight | — |
| Dec 15, 2025 | Barclays | Equal-Weight | — |
| Nov 11, 2025 | Piper Sandler | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Sep 16, 2026
Pacific Biosciences of California, Inc. (PACB) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 4:50 PM EDTCompany...
Yahoo · Sep 14, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Yahoo · Sep 10, 2026
Pacific Biosciences of California (PACB) closed at $1.27 in the latest trading session, marking a -1.55% move from the prior day.
Benzinga · Sep 9, 2026
UBS analyst Doug Schenkel assumes Pacific Biosciences (NASDAQ:PACB) with a Neutral rating and lowers Price Target of $1.35.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PACB.
